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Abstract
Background
Easily identifiable risk factors including: obesity and ethnicity at high risk of diabetes are
commonly used to indicate which women should be offered the oral glucose tolerance test
(OGTT) to diagnose gestational diabetes (GDM). Evidence regarding these risk factors is
limited however. We conducted a systematic review (SR) and meta-analysis and individual
participant data (IPD) analysis to evaluate the performance of risk factors in identifying
women with GDM.
Methods
We searched MEDLINE, Medline in Process, Embase, Maternity and Infant Care and the
Cochrane Central Register of Controlled Trials (CENTRAL) up to August 2016 and con-
ducted additional reference checking. We included observational, cohort, case-control and
cross-sectional studies reporting the performance characteristics of risk factors used to
identify women at high risk of GDM. We had access to IPD from the Born in Bradford and
Atlantic Diabetes in Pregnancy cohorts, all pregnant women in the two cohorts with data on
risk factors and OGTT results were included.
Results
Twenty nine published studies with 211,698 women for the SR and a further 14,103 women
from two birth cohorts (Born in Bradford and the Atlantic Diabetes in Pregnancy study) for
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the IPD analysis were included. Six studies assessed the screening performance of guide-
lines; six examined combinations of risk factors; eight evaluated the number of risk factors
and nine examined prediction models or scores. Meta-analysis using data from published
studies suggests that irrespective of the method used, risk factors do not identify women
with GDM well.
Using IPD and combining risk factors to produce the highest sensitivities, results in low
specificities (and so higher false positives). Strategies that use the risk factors of age (>25
or >30) and BMI (>25 or 30) perform as well as other strategies with additional risk factors
included.
Conclusions
Risk factor screening methods are poor predictors of which pregnant women will be diag-
nosed with GDM. A simple approach of offering an OGTT to women 25 years or older and/
or with a BMI of 25kg/m2 or more is as good as more complex risk prediction models.
Research to identify more accurate (bio)markers is needed.
Systematic Review Registration: PROSPERO CRD42013004608
Introduction
Gestational diabetes mellitus (GDM) is hyperglycaemia of variable severity first identified in
pregnancy. GDM is associated with an increased risk of a range of adverse perinatal outcomes,
[1,2] including being born large (macrosomia) and there is growing evidence that the longer-
term health of the mother and infant may be adversely affected.[3–5]
Treatment of GDM improves perinatal outcomes,[6–8] suggesting a role for identifying
women with GDM. There is uncertainty about the effectiveness of different strategies for iden-
tifying these women, largely because of the lack of good quality evidence.[8,9] This has led to
variation in clinical guidelines and practice for identifying GDM, both between and within
countries. Strategies include selectively offering a 75g or 100g oral glucose tolerance test
(OGTT) to high risk women only, identified using specific risk factors (usually easily identifi-
able maternal characteristics) or the administration of a 50g glucose challenge test. Alterna-
tively all women can be offered an OGTT (universal offer of OGTT).[10,11] Restricting
diagnostic testing to high risk women may be less costly than offering testing to all; the OGTT
is relatively expensive and requires pregnant women to fast overnight and attend clinic for at
least two hours. However, offering all women an OGTT may result in more women with
GDM being identified and a reduction in adverse outcomes, as more affected women will
receive treatment to reduce hyperglycaemia. GDM is also a risk factor for later development of
type 2 diabetes,[3] if more women with GDM are identified, more could receive interventions
aimed at reducing these risks and alongside lifelong screening to identify type 2 diabetes ear-
lier, associated morbidities and costs may be reduced, however there is no robust evidence of
longer-term benefit from the identification of GDM using a universal testing strategy.[8]
Risk factor screening involves the assessment of maternal characteristics, such as family his-
tory of diabetes; being of an ethnicity with a high prevalence of diabetes (i.e. non-white ethnic-
ity: including Asian, black Caribbean or Middle Eastern); history of having GDM or a
macrosomic infant; maternal obesity[12] and occasionally biochemical markers.[13,14]
Risk factor screening to identify women requiring OGTT to diagnose gestational diabetes
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Several healthcare agencies including the UK National Institute for Health and Care Excel-
lence (NICE)[12], the American diabetes Association[15] and the Australasian Diabetes in
Pregnancy Society (ADIPS)[16] recommend offering an OGTT to women with one or more
risk factors (Table 1) in early pregnancy, some agencies then recommend repeat testing in this
high risk group of women (those with risk factors), if GDM has not already been identified,
[12] whilst others recommend all women (not previously identified as having GDM in early
pregnancy) are offered an OGTT irrespective of risk factors.[16,17] For the majority of women
the OGTT is conducted in mid-pregnancy (usually at 24–28 weeks gestation) so that the maxi-
mum number of women destined to develop hyperglycaemia will have a chance to be detected,
while allowing enough time to provide treatment.
Risk factor assessment is recommended in many populations in early pregnancy. The pres-
ence of a risk factor therefore influences early assessment of hyperglycaemia and whether mid-
trimester testing in selectively tested populations is conducted. The aim of this study was to
evaluate the performance of risk factors in identifying women requiring diagnostic testing for
GDM, utilising published studies and available individual participant data.
Methods
We conducted a systematic review and meta-analyses of published studies evaluating risk fac-
tors for the identification of women at high risk of GDM. The review was conducted in accor-
dance with the Centre for Reviews and Dissemination’s guidance[18]. We also analysed
individual participant data (IPD) from two large birth cohorts: Born in Bradford (BiB)[19]
and Atlantic Diabetes in Pregnancy (Atlantic DIP)[20]. The methods and results are reported
following the PRISMA guidelines (S1 File).[21]
Search strategy
Title, abstract screening and then full text screening was performed in duplicate by two review-
ers (DF, MS, SG or MB) with disagreements resolved by consensus or by a third reviewer.
Search: identification of studies from the systematic review
Searches were undertaken up to August 2016 in MEDLINE, MEDLINE in-process, Embase,
Maternity and Infant Care and CENTRAL with no date or country restrictions (S2 File). In
addition to database searches, citation checking of included publications was undertaken.
Study selection: Inclusion and exclusion criteria
All eligible published and on-going observational, cohort, case-control or cross-sectional studies
were included. Due to time and cost constraints only studies published in English were included.
Studies had to report data from women in whom risk factors for GDM were recorded and who
were tested for GDM using an OGTT. We included studies that evaluated readily available/rou-
tinely collected maternal characteristics: age, ethnicity, parity, previous GDM, macrosomia, fam-
ily history of diabetes, BMI and blood pressure. We did not include studies that focused solely
on biochemical tests such as the 50g oral glucose challenge test, as these tests are less commonly
used in universal pre-diagnostic test screening programmes and are more costly than risk factor
screening.[12] We examined the value of using combinations of risk factors for selecting preg-
nant women for OGTT. Studies had to report the accuracy of combinations of risk factors; such
as, numbers of risk factors present, risk models or scores based or measuring multiple risk fac-
tors, or the use of guideline recommendations. Studies reporting the screening accuracy of a sin-
gle risk factor, without examining combinations of risk factors, were excluded.
Risk factor screening to identify women requiring OGTT to diagnose gestational diabetes
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Table 1. Summary of selected screening strategies recommending the use of risk factors for the iden-
tification of gestational diabetes.
Agency Nature of screening strategy
National Institute for Health and Care
Excellence (UK NICE)[12] 2015
Offer women who have had GDM previously self-monitoring,
blood glucose estimation or OGTT in early pregnancy.Offer
OGTT at 24–28 weeks gestation only to women with at least
one of:BMI >30kg/m2
• Previous macrosomic baby (above 4.5kg)
• Previous GDM
• Family history of diabetes
• Ethnic origin with a high prevalence of diabetes
American Diabetes Association(ADA)[17]
2017
Offer OGTT at first pregnancy visit to women who are
overweight/obese (BMI25 kg/m2) or are Asian American and
have at least one additional risk factor:
• A1C5.7% (39 mmol/mol), IGT, or IFG on previous testing
• first-degree relative with diabetes
• High-risk race/ethnicity (e.g., African American, Latino, Native
American, Asian American, Pacific Islander)
• Women who were diagnosed with GDM
• History of CVD
• Hypertension (140/90 mmHg or on therapy for
hypertension)
• HDL cholesterol level, 35 mg/dL (0.90 mmol/L) and/or a
triglyceride level .250 mg/dL(2.82 mmol/L)
• Women with polycystic ovary syndrome
• Physical inactivity
• Other clinical conditions associated with insulin resistance
(e.g., severe obesity, acanthosis nigricans
Test all women at 24 to 28 weeks gestation not previously
known to have diabetes
Australasian Diabetes in Pregnancy
Society (ADIPS)[16] 2014
Offer OGTT early in pregnancy to women who have a BMI
25kg/m2 or are from an ethnicity at high risk of diabetes (e.g.
Asian, Aboriginal, Pacific Islander) and who have an abnormal
fasting or random blood sugar
Offer OGTT early in pregnancy to women with one of the risk
factors below or who have both a BMI25kg/m2 and are from
an ethnicity at high risk of diabetes (e.g. Asian, Aboriginal,
Pacific Islander)
• Previous GDM
• Previously elevated blood glucose level
• Age40 years
• High-risk race/ethnicity
• Family history of diabetes
• Pre-pregnancy BMI > 35 kg/m2
• Previous macrosomia
• Polycystic ovarian syndrome
• Medications: corticosteroids, antipsychotics
Offer OGTT to all women at 24 to 28 weeks gestation not
already identified as having GDM
IGT = impaired glucose tolerance test; IFG = impaired fasting glucose; BMI = body mass index;
A1C = glycated haemoglobin; CVD = cardiovascular disease
https://doi.org/10.1371/journal.pone.0175288.t001
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No formal quality assessment process was undertaken because of the lack of any validated
quality assessment tool for studies evaluating the performance of risk factors as a screening
test; however studies had to report adequate information and that information had to be in a
format that allowed comparison with others (described below in statistical analysis).
Data extraction
Data were extracted by three reviewers (MS, SG, DF) and any disagreements resolved through
discussion. Publication year, location, GDM diagnostic criteria, risk factors, cut-off levels of
risk factors if appropriate and number of women included with risk factor combinations were
recorded. The total number of women with and without GDM according to diagnostic test
results and assessment of risk factor performance (sensitivity and specificity and positive pre-
dictive value, if reported) were recorded.
Statistical analysis
For each group of risk factor combinations, sensitivity (proportion of GDM cases correctly
identified by the risk factor); specificity (proportion of women without GDM correctly identi-
fied) and positive rate (proportion of women who would be offered an OGTT if the risk factor
combinations were present) were calculated. Statistics were plotted for each study in Receiver
Operating Characteristic (ROC) space, by plotting screening performance—sensitivity against
positive rate.[22] A ‘good’ test will have high sensitivity with small numbers needing to be
tested (with results near the top left of the space). Meta-analysis methods for pooling of screen-
ing studies, such as the Hierarchical summary receiver-operator curves (HSROC) model [23]
were considered, but not performed because of the different screening approaches and
included risk factors used by studies.
Individual participant data (IPD) cohort analysis
Data from two birth cohorts were eligible and available. Born in Bradford (BiB) [19] is a pro-
spective birth cohort (research ethics committee approval reference 07/H1302/112); the meth-
ods have been previously described.[19] The Atlantic Diabetes in Pregnancy study (Atlantic
DIP) is a multi-centre cohort study comprising of a partnership of five hospitals at the Irish
Atlantic seaboard (research ethics committee approval was obtained from participating cen-
tres); study methods have been previously described.[20] Both cohorts offered all women a 75g
OGTT irrespective of the presence of risk factors. The World Health Organization (WHO)
1999 (modified) criteria were used to diagnose GDM (fasting glucose6.1mmol/l, two-hour
post-load glucose7.8mmol/l) in both cohorts.[24,25]
Statistical analysis
Risk factors recorded by the IPD cohorts were similar to those recorded by published studies
included in the systematic review. We considered seven commonly used risk factors: age; BMI;
parity (multiparous, primiparous); ethnicity (White, South Asian or Other), family history of
diabetes; previous GDM or having had a previous macrosomic infant. We grouped women
into white (British/Irish), south Asian or other, as these groupings most appropriately repre-
sent the ethnicities of the women in the included cohorts, it should be noted that these group-
ings may not be appropriate for other populations. Data on previous GDM or having had a
previous macrosomic infant were not available in the Atlantic DIP cohort.
We classified BMI using the thresholds of 25kg/m2 (kilogramme/meter2) or over, or 30kg/
m2 or over; because these are the recommended thresholds for overweight and obesity.[26,27]
Risk factor screening to identify women requiring OGTT to diagnose gestational diabetes
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We used the age categories of 25 years or older, or 30 years or older, because they have been
used previously [28–31] and are clinically relevant. This generated 287 combinations of risk
factors. The sensitivity, specificity and positive rate were calculated for each combination of
risk factors and those that were “dominated” by another in that class (i.e. a combination is
dominated if there is one other related ‘test’ with both higher sensitivity and specificity which
would be a better predictor) were removed. Sensitivity and positive rates for the remaining
non-dominated tests were plotted in ROC space.
In addition we also examined screening performance based on a predicted risk of GDM,
similar to screening strategies used to identify those at risk of cardiovascular disease.[32] A
logistic regression model was fitted to data from each of the cohorts and to a pooled cohort
dataset for comparison, regressing GDM incidence against the seven included risk factors. The
resulting log odds ratios were used to calculate a predicted risk of GDM for each woman in the
dataset. The sensitivity and positive rate for predicting GDM at each percentage point of risk
from 1% to 80% was calculated and plotted in ROC space.
Results
Systematic review and meta-analysis
Searches identified 4272 unique citations (7858 before de-duplication). Thirteen additional
publications were identified through reference checking. After title and abstract screening, 225
publications were retrieved for full-text screening. One hundred and ninety six full text papers
were excluded because they did not meet eligibility criteria, leaving 29 studies (Fig 1), with
211,698 women. Six studies [33–38] assessed the screening performance of guideline recom-
mendations (UK National Institute for Health and Care Excellence (NICE),[37] American
Diabetes Association (ADA),[35–38] American College of Obstetricians and Gynecologists
(ACOG),[36] Australasian Diabetes In Pregnancy Society (ADIPS),[37] Irish,[33] French[34]).
Eight studies evaluated the screening performance of the number of risk factors (for example if
two, three or four etc. risk factors were present),[39–46] six examined combinations of risk
Fig 1. Flow chart of the systematic review search process.
https://doi.org/10.1371/journal.pone.0175288.g001
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factors[28,47–51] and nine studies examined the ability of a risk prediction model or a risk
score to predict GDM. [52–60]
All studies were observational, consisting of a mix of prospective and retrospective cohort
studies, with GDM diagnosed using an OGTT, using specified diagnostic criteria. Diagnostic
criteria and glucose thresholds varied between studies, which influenced estimates of GDM
prevalence. Studies were diverse in their included populations (Table 2).
Performance of risk factors in predicting GDM
Figs 2 to 4 show estimates of sensitivity and proportion of women that would be offered an
OGTT for each of the included studies, plotted in the ROC space. Fig 2 includes data from all
29 studies and shows, as one would expect, that the proportion of correctly identified GDM
cases (sensitivity) increases with the number of women offered an OGTT, irrespective of the
risk factor strategy used, there seems to be no obvious ‘best’ approach.
Fig 3 shows the proportion of correctly identified GDM cases and proportion offered an
OGTT for different screening recommendations (American College of Obstetricians and
Gynecologists (ACOG), American Diabetes Association (ADA), Australasian Diabetes in
Pregnancy Society (ADIPS) and the UK National Institute for Health and Care Excellence
(NICE)). There is considerable variation in both sensitivity and number of women offered an
OGTT. The screening performance of guideline recommendations appears moderate at best,
because generally at least 70% of women would need to be offered an OGTT to identify 80% of
all women with GDM, with the exception of the ACOG guideline when applied to an Irish[33]
or Spanish[36] population and the ADA guideline when applied to an Irish population.[33]
Fig 4 shows the results from eight studies that examined the sensitivity and number of
women offered an OGTT after the application of a risk prediction model or risk score. [52–57]
Each study has several points on the ROC curve because results are reported for various levels
of risk. Results are reasonably consistent across studies with all points generally lying on a sim-
ilar ROC curve.
Figs 2 to 4 clearly show a trade-off; as sensitivity increases (and more women are identified),
the number needed to receive a diagnostic test also increases. For example Fig 4 shows that to
identify 80% of women with GDM (sensitivity of 80%) using a risk prediction model or risk
score, between 30% and 58% of women would need to undergo an OGTT (depending which
risk model is used); to achieve a sensitivity of over 90%, nearly all women would need to
undergo an OGTT.
Individual participant data analysis
Screening based on combinations of risk factors. Fig 5 shows the percentage of GDM
cases identified (sensitivity) against percentage of women offered an OGTT (positive rate) for
each group of risk factors not ‘dominated’ by others. Irrespective of the number of risk factors
included (one risk factor through to the use of four); all groups generally lay on the same ROC
curve.
Fig 5 shows that using multiple risk factors is not superior to using just one or two, because
the increase in sensitivity is only achieved by increasing the number of women offered an
OGTT. Both cohorts demonstrate generally similar estimates of sensitivity and positive rate
for each number of risk factors.
Table 3 shows examples of the performance of combinations of risk factors (two, through
to four, not dominated) with sensitivity between 90% and 95% (detecting almost all cases of
GDM) and for the UK NICE guideline recommended group of risk factors.[12] A woman is
test positive (and therefore would be offered an OGTT) if she has one or more of the named
Risk factor screening to identify women requiring OGTT to diagnose gestational diabetes
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Table 2. Characteristics of studies included in the systematic review.
First author Year Country GDM diagnosis criterion Total women No. with GDM % with GDM Risk factor screening strategy
Avalos[33] 2013 Ireland IADPSG 5500 521a 9 Irish, NICE, ADA guideline recommendations
491b 9
585c 11
Caliskan[39] 2004 Turkey NDDG 422 14 3 Number of risk factors
Cosson[34] 2013 France WHO 18755 2710 14 French guideline recommendations
Cypryk[40] 2008 Poland WHO 2180 510 23 Number of risk factors
Danilenko-Dixon[35] 1999 USA NDDG 18504 564 3 ADA guideline recommendations
Erum[51] 2015 Turkey ADA 815 39 5 ‘At least one risk factor’
Gabbay-Benviz[58] 2015 USA C&C 924 63 7 Risk score
Jensen[61] 2003 Denmark DPSG 2992d 83 3 Number of risk factors
Jiminez-moleon[36] 2002 Spain NDDG 1436 58c 4 ADA and ACOG guideline recommendations
2174 63e 3
Kirke[59] 2014 Australia WHO 1636 73 4 Risk score
Marquette[42] 1985 USA C&C 434 12 3 Number of risk factors
Moses[47] 1998 Australia ADIPS 2907 183 6 Age, BMI ethnicity
Nanda[52] 2011 UK WHO 11464 297 3 Risk model
Naylor[53] 1997 US NDDG or C&C 1571 69 4 Risk score
Nielsen[43] 2016 India WHO 3946 659 17 Number of risk factors (1, 2 or 3)
Ostlund[28] 2003 Sweden WHO 3616 61 5 "Traditional risk factors"
Phaloprakam[54] 2009 Thailand C&C 469 127 27 Risk score
Pintaudi[48] 2014 Italy IADPSG 1015 113 11 "Standard risk factors"
Sacks[44] 1987 USA ADA 4116 138 3 Number of risk factors
Savona-Ventura[49] 2013 Mediterranean ADA 1368 119 9 Based on age, obesity or diastolic BP
Shamsuddin[45] 2001 Malaysia OGTT levels reported 768 191 25 Number of risk factors
Shirazian[55] 2009 Iran ADA 924 68 7 Risk score
Sunsaneevithayakul
[46]
2003 Thailand Not reported 9325 235 2 Number of risk factors
Syngelaki[60] 2015 UK WHO 75161 1827 20 Risk model
Teh[37] 2011 Australia ADIPS 2426 250 10 NICE, ADA and ADIPS guideline
recommendations
van Leeuwen[57] (A) 2010 Netherlands OGTT/GCT levels
reported
995 24 2 Risk model
van Leeuwen[56] (B) 2009 Netherlands WHO 1266 47 4 Risk score
Williams[50] 1999 USA NDDG 25118 210f 1 Based on age, BMI ethnicity, family history
Yang[38] 2002 China WHO 9471 171 2 ADA guideline
aIrish guideline
bNICE guideline
cADA recommendations
dJensen (2003), 5235 women were included in the study, 2992 had an OGTT performed
eACOG recommendations
fWilliams (1999), number of women with GDM varied by the recorded risk factor (i.e. not all women had all risk factors recorded)
ACOG = American College of Obstetricians and Gynecologists
ADA = American Diabetes Association
ADIPS = Australasian Diabetes In Pregnancy Society
C&C = Carpenter and Coustan
NDDA = National Diabetes Data Group
NICE = National Institute for Health and Care Excellence
IADPSG = International Association of Diabetes in Pregnancy Study Groups
WHO = World Health Organization
https://doi.org/10.1371/journal.pone.0175288.t002
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Fig 2. Screening performance (sensitivity and percentage offered an oral glucose tolerance test
(OGTT)) by study and by risk factor method (guideline recommendations, number (No) of risk factors,
‘other method and risk model/score). The colour of the points indicates the study. The shape of the points
(circles, triangle, square, cross) indicates method used No. RF = number of risk factors (i.e. presence of one
risk factor, two risk factors and so on). Studies may report more than one performance estimate, this is
reflected in the number of coloured shapes for each study.
https://doi.org/10.1371/journal.pone.0175288.g002
Fig 3. Screening performance of guidelines using a risk factor screening strategy. Vertical and horizontal
lines show the 95% confidence intervals for sensitivity and positive rate respectively. The colour of the points
indicates the study. The shape of the points (circles, triangle, square, cross) indicates method used. RF = Risk
factor, No = number. ACOG = American College of Obstetricians and Gynecologists. ADA = American Diabetes
Association. ADIPS = Australasian Diabetes In Pregnancy Society. NICE = National Institute for Health and
Care Excellence. Studies may report more than one performance estimate, this is reflected in the number of
coloured shapes for each study.
https://doi.org/10.1371/journal.pone.0175288.g003
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risk factors in each group. Combining risk factors to produce the highest sensitivities, results
in low specificities (and so higher false positives). Strategies that use only age and BMI catego-
ries however, perform similarly to others with additional risk factors. In our analyses, the
NICE guideline recommended risk factor strategy was dominated by other strategies (other
strategies had superior performance). For example, using combined cohort data, screening
based on being either 25 years or older or having a BMI of 30 or over, achieved a higher sensi-
tivity than using the combined NICE guideline recommended risk factors (Table 1) (93.2%
and 78.2% respectively), but with a correspondingly higher positive rate (78.0% and 67.2%
respectively) and lower specificity (23.3% and 31.7% respectively).
Screening using risk prediction models. The odds ratios for the association between
each risk factor and GDM for each cohort are shown in Table 4. All risk factors examined,
apart from multiparity, were positively associated with GDM.
When considering risk factors available in both cohorts, the odds ratios were generally con-
sistent, with the exception of non-white/Irish ethnicity, the strength of the association being
more than twice that in Atlantic DIP than BiB (half the participants in BiB are of south Asian
(non-white) origin, half are white British, whereas few women in Atlantic DIP are non-white).
‘Having had GDM in a previous pregnancy’ was most strongly associated with GDM in BiB
(this risk factor was not available in Atlantic DIP).
The odds ratios shown in Table 4 were used to construct a predicted risk of GDM for each
woman in each cohort. The ROC curves of sensitivity against positive rate are shown in Fig 6
and are similar for the two cohorts, though the performance seems marginally better for Atlan-
tic DIP compared to BiB. The areas under the curves (AUCs) being 0.77 for Atlantic DIP and
0.72 for BiB, suggesting modest screening performance. Performance using a predictive risk
model (Fig 6) seems similar to using a combination of several risk factors.
Fig 4. Screening performance of risk prediction or scoring models. The colour of the points indicates the
study. Vertical and horizontal lines show the 95% confidence intervals for sensitivity and positive rate
respectively. Studies may report more than one performance estimate, this is reflected in the number of
coloured shapes for each study
https://doi.org/10.1371/journal.pone.0175288.g004
Risk factor screening to identify women requiring OGTT to diagnose gestational diabetes
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Discussion
To our knowledge, this is the first systematic review and meta-analysis to assess the predictive
accuracy of different combinations of risk factors to identify women at high risk of GDM. We
found that universal risk factor pre-diagnostic test screening can take a variety of forms, but
whatever the form, this strategy did not appear effective for accurately identifying women with
GDM. Furthermore we found no evidence that complex risk screening strategies using several
risk factors or risk prediction models offered significant benefit over the simpler strategy of
identifying one or two risk factors. Regardless of the methods used, correctly identifying most
women with GDM, requires offering an OGTT to the majority of women and therefore does
not vary considerably from offering all women an OGTT. For some populations however, lim-
iting the offer of an OGTT to high risk women may result in important cost savings.
Our IPD analyses suggest that the risk factor combination of maternal age and BMI (25
years or older and BMI25 kg/m2) would identify the majority of women with GDM, but
consistent with our systematic review findings, would mean inviting most women for an
OGTT. Although this is as effective as more complex strategies (risk prediction models for
example) it may not vary greatly from offering all women an OGTT.
Strengths and limitations
This study examined published data identified by a systematic search, comprising 29 studies
and including 211,689 women. We also conducted analyses using IPD from two large contem-
porary birth cohorts including 14,103 women. The findings from the published studies and
IPD cohorts were consistent with each other. As well as triangulating findings from these two
Fig 5. Screening performance of risk factor combinations for identifying GDM using IPD. The colour of
the points indicates the number (No) of risk factors included. Circles indicate results for Atlantic DIP and
triangles represent results for BiB.
https://doi.org/10.1371/journal.pone.0175288.g005
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different designs we also compared findings from two different analytical approaches and also
found consistency there, suggesting that our results are robust. Different populations based on
Table 3. Performance of risk factors, grouped by age, BMI and UK NICE categories for the identification of GDM using IPD
Risk factors Sensitivity Specificity Positive rate
BiB cohort
Age25 BMI30 90.4 28.7 72.7
Age25 BMI30, prior GDM 90.4 28.6 72.8
Age25 BMI30, FH of diabetes 91.6 23.2 77.7
Age25 BMI30, FH of diabetes, prior GDM 91.6 23.1 77.7
Age30, BMI30, non-white ethnicity 94.3 21.3 79.8
Age30, BMI30, non-white ethnicity, prior GDM 94.3 21.3 79.9
Age25, BMI25, FH of diabetes 94.4 16.9 83.8
Age25, BMI25, FH of diabetes, prior GDM 90.4 28.7 72.7
Atlantic DIP cohorta
BMI25, non-white ethnicity 90.1 36.8 66.0
Age30, BMI30 90.8 28.6 73.4
Age30, BMI30, non-white ethnicity 93.9 26.0 76.0
Cohorts combined
Age30, BMI30, FH of diabetes 90.0 24.6 76.4
Age30, BMI25, FH of diabetes, prior GDM 90.3 24.6 76.5
BMI25, non-white ethnicity 92.0 24.0 77.3
BMI25, non-white ethnicity, prior GDM 92.1 24.0 77.3
Age25, BMI30 93.2 23.3 78.0
Age25, BMI30, prior GDM 93.2 23.3 78.1
Age30, BMI30, non-white ethnicity 94.1 22.7 78.7
Age30, BMI30, non-white ethnicity, prior GDM 94.1 22.7 78.7
Age25, BMI25 95.9 16.5 84.5
Age25, BMI25, prior GDM 95.9 16.5 84.5
NICE guideline recommended risk factors[12] 78.2 31.7 67.2
BMI = body mass index (kg/m2)
FH = family history
NICE = National Institute for Health and Care Excellence
aPrevious macrosomia and GDM not available in Atlantic DIP
https://doi.org/10.1371/journal.pone.0175288.t003
Table 4. The associations between risk factors and GDM using IPD
BiB Atlantic DIP
Odds ratio 95% Confidence interval Odds ratio 95% Confidence interval
Risk factor
Age (per year)
1.09 1.08 − 1.1 1.10 1.07 − 1.12
BMI (per kg/m2) 1.06 1.05 − 1.08 1.13 1.11 − 1.15
Ethnicity (non-white) 2.32 1.90 − 2.83 5.16 3.85 − 6.91
Multiparity 0.89 0.73 − 1.08 0.74 0.58 − 0.96
Family history of diabetes 1.36 1.14 − 1.63 1.42 1.17 − 1.80
Previous macrosomiaa 1.54 1.12–2.13 - -
Previous GDMa 5.90 3.78–9.22 - -
anot available in Atlantic DIP
https://doi.org/10.1371/journal.pone.0175288.t004
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geography and age were included suggesting that our results might be broadly generalisable to
different antenatal populations in high income countries. Very few studies were from low
income countries and it is therefore important to note that our findings may not generalise to
those countries. Given the increase in non-communicable diseases in low and middle income
countries and the scarcity of resources to be able to adequately deal with them, there is clearly
a need to gain better understanding about how to screen for, diagnose and treat GDM in those
countries.
Recommendations regarding the identification of GDM vary and some institutions that pre-
viously recommended risk factor assessment now recommend offering all women an OGTT,
however there is a lack of supporting evidence that this strategy improves maternal and off-
spring health compared to selective testing high risk women [8] and given the likely increase in
associated costs, clinicians and commissioners may not be willing or able to accept universal
testing for GDM. The risk factors that we were able to assess in published studies were limited
by what was available, but they included a range of the commonly used risk factors for GDM.
Studies used varying threshold criteria and this influences the numbers of women identified by
risk factors and makes comparison complex. Applying the same criteria in dissimilar popula-
tions however will also produce varying results (see the NICE guideline results in Fig 3 and
Table 3). A more consistent global approach to identifying women with GDM would reduce
variation in practise and would likely improve care. Although our search did not identify any; it
is possible that there may be eligible studies published in languages other than English.
Conclusions and implications for practice
Our results suggest that pre-diagnostic risk factor screening is a poor method for identifying
women with GDM. Using this strategy will reduce the likely impact of antenatal GDM
Fig 6. Sensitivity and positive rate when using a risk prediction model to predict GDM using IPD
https://doi.org/10.1371/journal.pone.0175288.g006
Risk factor screening to identify women requiring OGTT to diagnose gestational diabetes
PLOS ONE | https://doi.org/10.1371/journal.pone.0175288 April 6, 2017 13 / 17
screening, testing and management programmes. Given these findings, there is an need for
research to develop and evaluate (bio)markers that might more accurately identify women at
high and low risk of GDM. Until then and if universal offer of an OGTT is not adopted, our
results suggest that using age with a cut-off of 25 years (i.e. referring women at or older than
25 years for an OGTT) or who have a BMI of25 or30 kg/m2 would be currently the sim-
plest and most accurate risk factor screening method. Ultimately though, the choice of whether
and how to identify GDM should be informed by rigorous cost-effectiveness analysis.
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